山东步长制药股份有限公司关于公司拟购买安宫牛黄丸药品生产技术相关事宜的进展公告

Transaction Overview - Shandong Buchang Pharmaceutical Co., Ltd. plans to acquire the production technology of An Gong Niu Huang Wan from Liaoning Hancao Tang Chinese Medicine Co., Ltd. for 8.4 million RMB to enrich its product line [2][4] - The formal contract for the transfer of production technology was signed on April 21, 2023, and the contract name was later revised to meet regulatory requirements [3][4] Progress of the Transaction - The company received approval from the National Medical Products Administration to change the marketing authorization holder for An Gong Niu Huang Wan from Liaoning Hancao Tang to Buchang Pharmaceutical in March 2025 [4] - The production site for An Gong Niu Huang Wan has been officially changed to the company's facility in Heze, Shandong Province, with the original formula and standards remaining unchanged [5][6] Sales Performance - Annual sales of An Gong Niu Huang Wan in sample hospitals from 2022 to 2024 were 230.76 million RMB, 241.39 million RMB, and 268.94 million RMB respectively [6] - Sales in urban pharmacies during the same period were 4.57 billion RMB, 5.38 billion RMB, and 4.42 billion RMB respectively [6] R&D Investment - The company has invested approximately 11.97 million RMB in research and development for the An Gong Niu Huang Wan product as of the date of the announcement [7] Impact on the Company - The change in production site is expected to enhance the company's business expansion and product line, thereby strengthening its market competitiveness without significantly impacting current operations [7]